The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Abstract
The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor of the ErbB family that is abnormally activated in many epithelial tumors. Receptor activation leads to recruitment and phosphorylation of several downstream intracellular substrates, leading to mitogenic signaling and other tumor-promoting cellular activities. In human tumors, receptor overexpression correlates with a more aggressive clinical course. Taken together, these observations indicate that the EGFR is a promising target for cancer therapy. Monoclonal antibodies directed at the ligand-binding extracellular domain and low–molecular weight inhibitors of the receptor’s tyrosine kinase are currently in advanced stages of clinical development. These agents prevent ligand-induced receptor activation and downstream signaling, which results in cell cycle arrest, promotion of apoptosis, and inhibition of angiogenesis. They also enhance the antitumor effects of chemotherapy and radiation therapy. In patients, anti-EGFR agents can be given safely at doses that fully inhibit receptor signaling, and single-agent activity has been observed against a variety of tumor types, including colon carcinoma, non–small-cell lung cancer, head and neck cancer, ovarian carcinoma, and renal cell carcinoma. Although antitumor activity is significant, responses have been seen in only a minority of the patients treated. In some clinical trials, anti-EGFR agents enhanced the effects of conventional chemotherapy and radiation therapy. Ongoing research efforts are directed at the selection of patients with EGFR-dependent tumors, identification of the differences among the various classes of agents, and new clinical development strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Signal Transduction through MAP Kinase Cascades
(1998) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60765-4 · Cited by 1,759
Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., & Ullrich, A. (1999) · Nature · doi:10.1038/47260 · Cited by 1,504
Cited by
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60735-0 · Cited by 3,908
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
Self-citationStructural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
ADAMs: key components in EGFR signalling and development
Blobel, C. P. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1548 · Cited by 1,090
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830
“In these patients, the tumor growth is likely to be driven predominantly by the EGFR pathway (6, 7).”
BackgroundRole of epidermal growth factor receptor in breast cancer
Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2289-9 · Cited by 806
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Mechanisms of cutaneous toxicities to EGFR inhibitors
Lacouture, M. E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1970 · Cited by 789
Han, S.-W., Kim, T.-Y., Hwang, P. G., Jeong, S., Kim, J., Choi, I. S., Oh, D.-Y., Kim, J. H., Kim, D.-W., Chung, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.388 · Cited by 768
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Self-citationEpidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Self-citationOvergaard, J., Hansen, H. S., Specht, L., Overgaard, M., Grau, C., Andersen, E., Bentzen, J., Bastholt, L., Hansen, O., Johansen, J., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14361-9 · Cited by 685
Pao, W., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 631
Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 591
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Robert, C., Soria, J.-C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., Wechsler, J., Lhomme, C., Escudier, B., Boige, V., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70243-6 · Cited by 554
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
Lo, H.-W., Hsu, S.-C., Ali-Seyed, M., Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J.-Y., & Hung, M.-C. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.007 · Cited by 544
Dittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Raju, U., Milas, L., Chen, D. J., Kehlbach, R., & Rodemann, H. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506591200 · Cited by 529
Lenz, H.-J., Van Cutsem, E., Khambata-Ford, S., Mayer, R. J., Gold, P., Stella, P., Mirtsching, B., Cohn, A. L., Pippas, A. W., Azarnia, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7595 · Cited by 528
Su, K.-Y., Chen, H.-Y., Li, K.-C., Kuo, M.-L., Yang, J. C.-H., Chan, W.-K., Ho, B.-C., Chang, G.-C., Shih, J.-Y., Yu, S.-L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3224 · Cited by 499
Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., & Armand, J.-P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.116 · Cited by 499
Baselga, J., Trigo, J. M., Bourhis, J., Tortochaux, J., Cortés-Funes, H., Hitt, R., Gascón, P., Amellal, N., Harstrick, A., & Eckardt, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.119 · Cited by 490
Self-citationTargeting Tyrosine Kinases in Cancer: The Second Wave
Baselga, J. (2006) · Science · doi:10.1126/science.1125951 · Cited by 478
Self-citationEpidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Impact of EGFR expression on colorectal cancer patient prognosis and survival
Spano, J.-P., Lagorce, C., Atlan, D., Milano, G., Domont, J., Benamouzig, R., Attar, A., Benichou, J., Martin, A., Morere, J.-F., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi006 · Cited by 462
Lynch, T. J., Patel, T., Dreisbach, L., McCleod, M., Heim, W. J., Hermann, R. C., Paschold, E., Iannotti, N. O., Dakhil, S., Gorton, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9618 · Cited by 447
Epidermal growth factor receptor inhibition strategies in oncology
Harari, P. M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00600 · Cited by 423
Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., Masi, G., Graziano, F., Cremolini, C., Rulli, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2796 · Cited by 403
Gefitinib — a novel targeted approach to treating cancer
Herbst, R. S., Fukuoka, M., & Baselga, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1506 · Cited by 401
Self-citationTam, I. Y. S., Chung, L. P., Suen, W. S., Wang, E., Wong, M. C. M., Ho, K. K., Lam, W. K., Chiu, S. W., Girard, L., Minna, J. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1981 · Cited by 400
Mamot, C., Drummond, D. C., Noble, C. O., Kallab, V., Guo, Z., Hong, K., Kirpotin, D. B., & Park, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1093 · Cited by 382
Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)
Huang, S., Armstrong, E. A., Benavente, S., Chinnaiyan, P., & Harari, P. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0562 · Cited by 366
Mao, L., Hong, W. K., & Papadimitrakopoulou, V. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00090-x · Cited by 365
Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. S., & Strasser, A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040316 · Cited by 343
Lynch, T. J., Kim, E. S., Eaby, B., Garey, J., West, D. P., & Lacouture, M. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-610 · Cited by 341
Rowinsky, E. K., Schwartz, G. H., Gollob, J. A., Thompson, J. A., Vogelzang, N. J., Figlin, R., Bukowski, R., Haas, N., Lockbaum, P., Li, Y.-P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.061 · Cited by 329
A Sense of Danger from Radiation1
McBride, W. H., Chiang, C.-S., Olson, J. L., Wang, C.-C., Hong, J.-H., Pajonk, F., Dougherty, G. J., Iwamoto, K. S., Pervan, M., & Liao, Y.-P. (2004) · Radiation Research · doi:10.1667/rr3196 · Cited by 323
Fuchs, B. C., Fujii, T., Dorfman, J. D., Goodwin, J. M., Zhu, A. X., Lanuti, M., & Tanabe, K. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2460 · Cited by 309
Sheehan, K. M., Calvert, V. S., Kay, E. W., Lu, Y., Fishman, D., Espina, V., Aquino, J., Speer, R., Araujo, R., Mills, G. B., et al. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t500003-mcp200 · Cited by 306
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Crombet, T., Osorio, M., Cruz, T., Roca, C., del Castillo, R., Mon, R., Iznaga-Escobar, N., Figueredo, R., Koropatnick, J., Renginfo, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.089 · Cited by 296
Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?
Gazdar, A. F., Shigematsu, H., Herz, J., & Minna, J. D. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.08.008 · Cited by 293
PCNA: a silent housekeeper or a potential therapeutic target?
Wang, S.-C. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.02.004 · Cited by 285
Chan, A. T. C., Hsu, M.-M., Goh, B. C., Hui, E. P., Liu, T.-W., Millward, M. J., Hong, R.-L., Whang-Peng, J., Ma, B. B. Y., To, K. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.147 · Cited by 287
Phage display screening of therapeutic peptide for cancer targeting and therapy
Saw, P. E., & Song, E.-W. (2019) · Protein & Cell · doi:10.1007/s13238-019-0639-7 · Cited by 279
Matar, P., Rojo, F., Cassia, R., Moreno-Bueno, G., Di Cosimo, S., Tabernero, J., Guzmán, M., Rodriguez, S., Arribas, J., Palacios, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0870 · Cited by 277
Self-citationGan, Y., Shi, C., Inge, L., Hibner, M., Balducci, J., & Huang, Y. (2010) · Oncogene · doi:10.1038/onc.2010.240 · Cited by 266
Khambata-Ford, S., Harbison, C. T., Hart, L. L., Awad, M., Xu, L.-A., Horak, C. E., Dakhil, S., Hermann, R. C., Lynch, T. J., & Weber, M. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2890 · Cited by 266
Skin toxicities associated with epidermal growth factor receptor inhibitors
Li, T., & Perez-Soler, R. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0114-0 · Cited by 261
Osborne, C., Wilson, P., & Tripathy, D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-361 · Cited by 257
Han, S.-W., Kim, T.-Y., Jeon, Y. K., Hwang, P. G., Im, S.-A., Lee, K.-H., Kim, J. H., Kim, D.-W., Heo, D. S., Kim, N. K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2845 · Cited by 253
Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., Mendelsohn, J., & Fan, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0589 · Cited by 170
Self-citationTargeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedScaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3407 · Cited by 151
Self-citationFan, Y.-F., Zhang, W., Zeng, L., Lei, Z.-N., Cai, C.-Y., Gupta, P., Yang, D.-H., Cui, Q., Qin, Z.-D., Chen, Z.-S., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.021 · Cited by 116
Darmoul, D., Gratio, V., Devaud, H., Peiretti, F., & Laburthe, M. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.514.2.9 · Cited by 109
Damiano, V., Caputo, R., Bianco, R., D'Armiento, F. P., Leonardi, A., De Placido, S., Bianco, A. R., Agrawal, S., Ciardiello, F., & Tortora, G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1943 · Cited by 90
Molecular pathways: sensitivity and resistance to anti-EGFR antibodies
Bertotti, A., & Sassi, F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0848 · Cited by 45
Cavazzoni, A., Alfieri, R. R., Cretella, D., Saccani, F., Ampollini, L., Galetti, M., Quaini, F., Graiani, G., Madeddu, D., Mozzoni, P., et al. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-91 · Cited by 44
“Cetuximab is a chimeric IgG1 monoclonal antibody (mAb) that blocks ligand binding to EGFR, leading to a decrease in receptor dimerization, autophosphorylation, and activation of signaling pathways [9].”
BackgroundLim, Y., Yoo, J., Kim, M.-S., Hur, M., Lee, E. H., Hur, H.-S., Lee, J.-C., Lee, S.-N., Park, T. W., Lee, K., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0679 · Cited by 38
Degradation of HER2 by Cbl-Based Chimeric Ubiquitin Ligases
Li, X., Shen, L., Zhang, J., Su, J., Shen, L., Liu, X., Han, H., Han, W., & Yao, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3731 · Cited by 37
Wheler, J. J., Tsimberidou, A. M., Falchook, G. S., Zinner, R. G., Hong, D. S., Fok, J. Y., Fu, S., Piha-Paul, S. A., Naing, A., & Kurzrock, R. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1208 · Cited by 34
Mallmann-Gottschalk, N., Sax, Y., Kimmig, R., Lang, S., & Brandau, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194693 · Cited by 31
Metadata
- Authors
- Mendelsohn, J., & Baselga, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-07-15
- Volume
- 21
- Issue
- 14
- Pages
- 2787-2799
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2039633811
- Cited by
- 1,255
- References
- 83
- FWCI
- 45.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.